Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Change in Account Payables: 2018-2025

Historic Change in Account Payables for Organogenesis Holdings (ORGO) over the last 8 years, with Sep 2025 value amounting to -$994,000.

  • Organogenesis Holdings' Change in Account Payables rose 74.35% to -$994,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 273.88%. This contributed to the annual value of -$2.4 million for FY2024, which is 2096.30% down from last year.
  • Organogenesis Holdings' Change in Account Payables amounted to -$994,000 in Q3 2025, which was down 124.05% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Change in Account Payables ranged from a high of $4.5 million in Q3 2021 and a low of -$4.4 million during Q1 2024.
  • Its 3-year average for Change in Account Payables is -$167,000, with a median of -$994,000 in 2025.
  • As far as peak fluctuations go, Organogenesis Holdings' Change in Account Payables surged by 442.54% in 2022, and later crashed by 2,975.40% in 2024.
  • Quarterly analysis of 5 years shows Organogenesis Holdings' Change in Account Payables stood at -$1.4 million in 2021, then slumped by 43.96% to -$2.0 million in 2022, then soared by 277.56% to $3.6 million in 2023, then rose by 2.73% to $3.6 million in 2024, then surged by 74.35% to -$994,000 in 2025.
  • Its Change in Account Payables stands at -$994,000 for Q3 2025, versus $4.1 million for Q2 2025 and -$2.5 million for Q1 2025.